Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

AbelZeta Forms a China CAR-T Collaboration with AstraZeneca

publication date: Dec 8, 2023

AbelZeta Pharma, a Maryland-Shanghai CAR-T company, will co-develop C-CAR031 in China with AstraZeneca. C-CAR031 is an autologous, armored GPC3-targeting CAR-T therapy aimed at treating hepatocellular carcinoma (HCC). The candidate was designed by AstraZeneca and is manufactured by AbelZeta in China. AbleZeta was previously known as CBMG, but it has sold its portfolio of stem cell drugs that is now developing a portfolio of 10 CAR-T candidates. When CBMG changed its focus to CAR-T, Janssen announced a $250 million upfront deal for a CAR-T and AstraZeneca invested $120 million in the company. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital